---
title: "Thymulin"
canonical_url: https://peptidelibrary.app/library/thymulin
description: "Zinc-dependent thymic nonapeptide, also called facteur thymique serique, secreted by thymic epithelial cells. It is biologically inactive until zinc binds and fixes it in the active conformation, so its activity tracks zinc status as well as peptide concentration. It has been studied for T-cell differentiation and, separately, for anti-inflammatory and antinociceptive effects in animal models. Circulating levels fall with age as the thymus involutes. Not FDA-approved as a drug."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Thymulin

Thymulin (also called Facteur thymique serique or FTS) is a thymic nonapeptide. Thymulin is a nonapeptide secreted by thymic epithelial cells whose defining feature is an absolute requirement for zinc: the peptide is biologically inactive until a zinc ion binds and fixes it in the active conformation, so circulating activity tracks zinc status as well as peptide concentration.

Zinc-dependent thymic nonapeptide, also called facteur thymique serique, secreted by thymic epithelial cells. It is biologically inactive until zinc binds and fixes it in the active conformation, so its activity tracks zinc status as well as peptide concentration. It has been studied for T-cell differentiation and, separately, for anti-inflammatory and antinociceptive effects in animal models. Circulating levels fall with age as the thymus involutes. Not FDA-approved as a drug.

Also known as: Facteur thymique serique, FTS.

Categories: Experimental.

## Classification

- Type: Thymic nonapeptide / research
- Mechanism class: Thymic Peptide
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Thymulin is a nonapeptide secreted by thymic epithelial cells whose defining feature is an absolute requirement for zinc: the peptide is biologically inactive until a zinc ion binds and fixes it in the active conformation, so circulating activity tracks zinc status as well as peptide concentration. In its active form it promotes T-cell differentiation and maturation, influences the balance of T-cell subsets, and modulates cytokine production. Separately it has been reported to have anti-inflammatory and antinociceptive activity in animal models through effects on neuroimmune signalling. Circulating thymulin falls with age as the thymus involutes. There are no controlled human efficacy trials.

Targets: T-cell differentiation pathways.

Origin: Endogenous nonapeptide; synthetic research material.

## Properties

- Sequence: Pyr-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn
- Molecular formula: C33H54N12O15
- Molecular weight: 858.9 g/mol
- CAS number: 63958-90-7
- Studied routes: Subcutaneous, Intravenous

## Evidence

- Evidence level: Limited Human Evidence
- Highest documented: Controlled human trials
- Human trials: 3
- Controlled human trials: 1
- Preclinical sources: 0
- Latest source: 1989

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Nonathymulin treatment of multiple sclerosis: double-blind pilot study. Acta Neurol Scand. 1989. 1989. Controlled human trial. Population: Adults with active multiple sclerosis and moderate disability (n=40, matched pairs). No difference from placebo in disability scores; no significant side effects recorded [Source](https://pubmed.ncbi.nlm.nih.gov/2618585/)
2. Improvement of cellular immunity and IgA production in immunodeficient children after treatment with synthetic serum thymic factor (FTS). Lancet. 1982. 1982. Human study (early or uncontrolled). Population: Children with IgA and IgE deficiency and T-cell defects (n=3). Fewer and milder infections and better cell-mediated immunity tests reported; gains regressed when treatment paused [Source](https://pubmed.ncbi.nlm.nih.gov/6124716/)
3. An open trial of thymulin (FTS-Zn) in rheumatoid arthritis patients: sequential clinical and immunological follow-up. Clin Exp Rheumatol. 1987. 1987. Human study (early or uncontrolled). Population: Patients with rheumatoid arthritis (number not stated in the indexed record). Not available in the indexed record [Source](https://pubmed.ncbi.nlm.nih.gov/3427844/)

## Safety

Side effects: Limited modern safety data.

Risks: Research-only.

Human safety basis: Limited human reports

Key limitations: No established human dosage.; Not approved by the FDA for any use..

## Regulatory status

Thymulin is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is Thymulin?

Zinc-dependent thymic nonapeptide, also called facteur thymique serique, secreted by thymic epithelial cells. It is biologically inactive until zinc binds and fixes it in the active conformation, so its activity tracks zinc status as well as peptide concentration. It has been studied for T-cell differentiation and, separately, for anti-inflammatory and antinociceptive effects in animal models. Circulating levels fall with age as the thymus involutes. Not FDA-approved as a drug.

### How does Thymulin work?

Thymulin is a nonapeptide secreted by thymic epithelial cells whose defining feature is an absolute requirement for zinc: the peptide is biologically inactive until a zinc ion binds and fixes it in the active conformation, so circulating activity tracks zinc status as well as peptide concentration. In its active form it promotes T-cell differentiation and maturation, influences the balance of T-cell subsets, and modulates cytokine production.

### Is Thymulin FDA approved?

No. Thymulin is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use. FDA's compounding lists show 503A Category 3: Nominated without adequate support.

### What is the amino acid sequence of Thymulin?

Thymulin has the sequence Pyr-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn, giving a chain of 9 amino acids. Its molecular formula is C33H54N12O15.

### What peptides are similar to Thymulin?

Compounds most often compared with Thymulin include Thymosin Alpha-1, Thymalin, Thymogen (Oglufanide) and Thymopentin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Role of thymulin or its analogue as a new analgesic molecule — Ann N Y Acad Sci, 2006](https://pubmed.ncbi.nlm.nih.gov/17192563/)
- [Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy — Nat Commun, 2026](https://pubmed.ncbi.nlm.nih.gov/42481458/)
- [Thymus-derived hormonal and cellular control of cancer — Front Endocrinol (Lausanne), 2023](https://pubmed.ncbi.nlm.nih.gov/37529610/)
- [Precursors of thymic peptides as stress sensors — Expert Opin Biol Ther, 2020](https://pubmed.ncbi.nlm.nih.gov/32700610/)
- [Thymulin (Zn-facteur thymique serique) activity in anorexia nervosa patients — Am J Clin Nutr, 1985](https://pubmed.ncbi.nlm.nih.gov/3927699/)
